Catestatin

Mechanism

A natural peptide fragment released from the adrenal glands that acts as an internal brake on stress hormones. It blocks the release of adrenaline and noradrenaline, helping to lower blood pressure and protect the heart. People with essential hypertension have been found to have lower levels of catestatin, suggesting it plays an important role in blood pressure regulation.

Effects

CARDIOVASCULAR SYSTEM: Potent antihypertensive — catestatin inhibits nicotinic acetylcholine receptor-mediated catecholamine release from chromaffin cells and sympathetic neurons, reducing norepinephrine and epinephrine output [in vitro, animal]. Reduces blood pressure in hypertensive animal models without affecting normotensive animals (physiological specificity) [animal]. Vasodilatory effects via stimulation of histamine release from mast cells (H1 receptor-mediated vasodilation) and direct endothelial nitric oxide production [animal, in vitro]. Cardioprotective during ischemia-reperfusion injury — reduces infarct size and improves cardiac function in rodent models via PI3K/Akt and NO/cGMP signaling [animal]. Inhibits cardiac fibrosis and hypertrophy in pressure-overload models [animal]. BIOMARKER POTENTIAL: Plasma catestatin levels are significantly reduced in essential hypertension — inverse correlation with blood pressure severity [clinical studies — O'Connor et al., 2002, 2008]. Low catestatin levels predict future development of hypertension in normotensive individuals (prospective data) [clinical]. Reduced in heart failure patients, correlating with disease severity [clinical]. Potential biomarker for sympathetic nervous system activity and cardiovascular risk stratification [clinical]. ANTIMICROBIAL: Broad-spectrum antimicrobial activity against S. aureus, P. aeruginosa, and C. albicans via membrane disruption — catestatin is a cationic antimicrobial peptide in addition to its cardiovascular role [in vitro]. METABOLIC: Anti-obesity effects in animal models — reduces hepatic fatty acid synthesis and inflammation [animal]. Improves insulin sensitivity and glucose tolerance in diet-induced obese mice [animal]. IMMUNE/INFLAMMATORY: Anti-inflammatory — suppresses macrophage-mediated inflammation, reduces TNF-α and IL-6 production [in vitro, animal]. Promotes wound healing via stimulation of angiogenesis and keratinocyte migration [animal].

Practitioner Guide

CLINICAL CONTEXT: Catestatin is NOT available as a therapeutic agent. It is an endogenous peptide (chromogranin A fragment, amino acids 352-372) being studied as both a biomarker and potential therapeutic target. No compounding pharmacies produce it. Clinical relevance is currently limited to understanding its biology and biomarker potential. BIOMARKER USE: Chromogranin A (CgA) blood testing is commercially available and used as a surrogate — elevated CgA in pheochromocytoma, neuroendocrine tumors, and carcinoid; CgA processing to catestatin may be impaired in hypertension. However, CgA is not the same as catestatin, and specific catestatin assays are research-only. SUPPORTING ENDOGENOUS CATESTATIN: Since catestatin is a chromogranin A fragment, strategies to support its production are indirect: stress management (chronic sympathetic activation depletes CgA stores), regular aerobic exercise (improves autonomic balance), adequate sleep (7-8h — sympathetic tone regulation), magnesium supplementation (300-600mg/day — modulates catecholamine release), and omega-3 fatty acids (2-3g/day — autonomic function support). TRANSLATIONAL GAP: The main barrier to therapeutic catestatin is delivery — it is a peptide that requires injection, has a short half-life in plasma (minutes), and the therapeutic dose in humans is unknown. No pharmaceutical company has advanced it to clinical trials as a therapeutic. The biomarker application is closer to clinical translation. HYPERTENSION MANAGEMENT: For patients with hypertension, catestatin biology supports the importance of sympatholytic approaches — meditation/mindfulness, deep breathing, adequate sleep, exercise, and stress reduction as adjuncts to standard antihypertensive therapy. GENETIC CONSIDERATIONS: Catestatin has known functional polymorphisms (Gly364Ser) that affect antimicrobial activity and cardiovascular risk — pharmacogenomic relevance for future personalized medicine.

Evidence

• Serum catestatin level in preeclampsia

  Authors not listed in queue metadata (2024) — Scripta Medica — PMID: 10.5937/scriptamed55-49730

  In 90 pregnant women, serum catestatin levels were lower in severe preeclampsia (29.01 ng/mL) than mild preeclampsia (43.67 ng/mL) and controls (59.96 ng/mL), suggesting inverse association with disease severity and biomarker potential.

  moderate

• Catestatin: Antimicrobial Functions and Potential Therapeutics

  Mahata SK et al. (2023) — Pharmaceutics

  This review synthesizes catestatin and cateslytin antimicrobial data, highlighting antibacterial, antifungal, antiyeast, and antibiotic-potentiating effects, plus low apparent resistance induction in experimental systems; it is useful contextual evidence but not a clinical efficacy trial.

  moderate

• The anti-inflammatory peptide Catestatin blocks chemotaxis

  Muntjewerff EM et al. (2022) — J Leukoc Biol — PMID: 34939227

  In vitro and in vivo migration assays showed catestatin blocks monocyte and neutrophil migration toward inflammatory chemokines CCL2 and CXCL2 and redirects CX3CR1+ macrophages away from pancreatic islets, supporting anti-inflammatory immunomodulatory activity.

  moderate

• Catestatin induces glycogenesis by stimulating the phosphoinositide 3‐kinase‐AKT pathway

  (2020) — Wiley — PMID: 10.1111/apha.13775

  Catestatin stimulates glycogen accumulation in liver and primary hepatocytes, enhances insulin signaling, and inhibits glycogenolysis induced by noradrenaline and adrenaline.

  emerging

• Catestatin: A Master Regulator of Cardiovascular Functions

  (2018) — Bentham Science Publishers Ltd. — PMID: 10.2174/0929867324666170425100416

  The study highlights the role of catestatin as a master regulator of cardiovascular functions, including its effects on blood pressure, heart rate variability, and cardioprotection. It also discusses the potential therapeutic applications of catestatin.

  moderate

• Plasma Catestatin in Patients with Acute Coronary Syndrome

  (2016) — S. Karger AG — PMID: 10.1159/000448987

  The study found that plasma catestatin levels were significantly lower in patients with STEMI and UAP compared to those without CAD. However, there were no significant differences in major adverse cardiovascular events (MACEs) between patients with high and low levels of catestatin.

  moderate

• Catestatin: A multifunctional peptide from chromogranin A

  (2010) — Elsevier BV — PMID: 10.1016/j.regpep.2010.01.006

  Catestatin is a multifunctional peptide that inhibits catecholamine secretion, acts as a vasodilator, and has antimicrobial and antimalarial properties. It is involved in the regulation of blood pressure, and its deficiency may contribute to the development of hypertension.

  anecdotal

• The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism.

  Angelone T, Quintieri AM, Brar BK, Limchaiyawat PT, Tota B, Mahata SK, Cerra MC. (2008) — Endocrinology — PMID: 18535098

  Catestatin dose-dependently increased heart rate and coronary pressure, and decreased left ventricular pressure. It also inhibited phospholamban phosphorylation and involved beta2-adrenergic receptors-Gi/o protein-nitric oxide-cGMP signaling mechanisms.

  emerging

• Proteolytic cleavage of human chromogranin A containing naturally occurring catestatin variants: differential processing at catestatin region by plasmin

  Biswas N et al. (2008) — Endocrinology — PMID: 17991725

  Plasmin processing of chromogranin A generated biologically active catestatin-region peptides, with less efficient cleavage in the Pro370Leu variant, linking catestatin processing biology to variant-specific cardiovascular-risk hypotheses.

  moderate

• Novel autocrine feedback control of catecholamine release. A discrete chromogranin A fragment is a noncompetitive nicotinic cholinergic antagonist.

  Mahata SK, O'Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, Gill BM, Parmer RJ. (1997) — J Clin Invest — PMID: 9294131

  Foundational catestatin study showing a chromogranin A fragment reversibly inhibited nicotinic-stimulated catecholamine release with IC50 about 200 nM, supporting an autocrine negative-feedback role in neuroendocrine secretion.

  moderate

Research Summary

TIER 1: Clinical studies demonstrating reduced plasma catestatin in essential hypertension (O'Connor et al., 2002 — original characterization; O'Connor et al., 2008 — prospective data). Clinical data showing catestatin as predictor of future hypertension development. No RCTs of exogenous catestatin administration in humans. TIER 2: Comprehensive reviews of catestatin biology and cardiovascular effects (Mahata et al., 2010, 2018). Animal study reviews showing cardioprotective, antihypertensive, and anti-obesity effects. Reviews of chromogranin A-derived peptides as a family. Structural and functional analysis of catestatin variants. TIER 3: Limited clinical case data. Research group observations from the UCSD chromogranin A program (Mahata, O'Connor). International data from Italian cardiovascular cohorts measuring catestatin levels. KEY FINDINGS: Catestatin is a genuinely promising cardiovascular biomarker with robust clinical correlation data. The biology is compelling — a natural sympatholytic peptide that reduces catecholamine release. However, the translational gap is wide — no therapeutic development has reached clinical trials. It exemplifies a common pattern in peptide biology: great biomarker, challenging therapeutic. GAPS: No human dosing data. Pharmacokinetics in humans unknown. No clinical trials as therapeutic agent. Uncertain whether exogenous catestatin can replicate the effects of endogenous production. Half-life stabilization strategies not developed. ACTIVE TRIALS: Primarily observational — studies measuring catestatin as biomarker in heart failure, metabolic syndrome, and hypertension cohorts. No interventional trials with catestatin administration.